Postwithdrawal rebound increase in T2 lesional activity in natalizumab-treated MS patients.
Vellinga
M M
MM
Department of Neurology, VU University Medical Center, de Boelelaan 1117, 1081 HV Amsterdam, the Netherlands. m.vellinga@vumc.nl
Castelijns
J A
JA
Barkhof
F
F
Uitdehaag
B M J
BM
Polman
C H
CH
D000328:Adult; D000911:Antibodies, Monoclonal / Q000008:administration & dosage / Q000009:adverse effects*; D061067:Antibodies, Monoclonal, Humanized; D001921:Brain / Q000187:drug effects* / Q000473:pathology*; D004311:Double-Blind Method; D004334:Drug Administration Schedule; D005260:Female; D006801:Humans; D007155:Immunologic Factors / Q000008:administration & dosage / Q000009:adverse effects; D008137:Longitudinal Studies; D008279:Magnetic Resonance Imaging; D008297:Male; D009103:Multiple Sclerosis / Q000188:drug therapy* / Q000473:pathology* / Q000503:physiopathology; D000069442:Natalizumab; D009413:Nerve Fibers, Myelinated / Q000187:drug effects / Q000276:immunology / Q000473:pathology; D010919:Placebos; D012008:Recurrence; D013375:Substance Withdrawal Syndrome / Q000473:pathology* / Q000503:physiopathology; D013995:Time
D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D007155:Immunologic Factors; D000069442:Natalizumab; D010919:Placebos